CAR-T Cell Therapies Might be Linked to Secondary Tumors

Highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) reported identified risk of secondary malignancies of T-cell origin and suggested patients treated with CAR-T cell therapy should receive life-long monitoring for secondary malignancies. This after the committee evaluated data on 38 cases of secondary malignancy of T-cell origin, including T-cell lymphoma and leukemia, reported among approximately 42,500 patients who have been treated with CAR T-cells. Tissue samples were tested in half of the cases, revealing the presence of the CAR construct in 7 cases, thus connecting the development of a secondary malignancy to the CAR T-cell medicine.